CO2022000186A2 - Nuevos compuestos heterocíclicos - Google Patents

Nuevos compuestos heterocíclicos

Info

Publication number
CO2022000186A2
CO2022000186A2 CONC2022/0000186A CO2022000186A CO2022000186A2 CO 2022000186 A2 CO2022000186 A2 CO 2022000186A2 CO 2022000186 A CO2022000186 A CO 2022000186A CO 2022000186 A2 CO2022000186 A2 CO 2022000186A2
Authority
CO
Colombia
Prior art keywords
heterocyclic compounds
compounds
new heterocyclic
new
processes
Prior art date
Application number
CONC2022/0000186A
Other languages
English (en)
Inventor
Uwe Grether
Hans Richter
Benoit Hornsperger
Carsten Kroll
Bernd Kuhn
Fionn O`Hara
Maurice Biedermann
Miroslav Kosar
Flore Reggiani
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2022000186A2 publication Critical patent/CO2022000186A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde R1, R2, X e Y son como se definen en la presente, composiciones que incluyen los compuestos, procesos para fabricar los compuestos y métodos para usar los compuestos.
CONC2022/0000186A 2019-07-09 2022-01-13 Nuevos compuestos heterocíclicos CO2022000186A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
CO2022000186A2 true CO2022000186A2 (es) 2022-01-17

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0000186A CO2022000186A2 (es) 2019-07-09 2022-01-13 Nuevos compuestos heterocíclicos

Country Status (18)

Country Link
US (1) US20220242876A1 (es)
EP (1) EP3997096A1 (es)
JP (1) JP2022539604A (es)
KR (1) KR20220034104A (es)
CN (1) CN114096545A (es)
AR (1) AR119376A1 (es)
AU (1) AU2020311584A1 (es)
BR (1) BR112021026899A2 (es)
CA (1) CA3145338A1 (es)
CL (1) CL2022000019A1 (es)
CO (1) CO2022000186A2 (es)
CR (1) CR20220004A (es)
IL (1) IL288987A (es)
MX (1) MX2022000243A (es)
PE (1) PE20220515A1 (es)
TW (1) TW202116781A (es)
WO (1) WO2021005034A1 (es)
ZA (1) ZA202110352B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
BR112022002375A2 (pt) 2019-09-12 2022-07-19 Hoffmann La Roche Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028474A1 (en) * 2011-08-19 2013-02-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2017087863A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3571202B1 (en) * 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
ZA202110352B (en) 2022-08-31
PE20220515A1 (es) 2022-04-07
US20220242876A1 (en) 2022-08-04
EP3997096A1 (en) 2022-05-18
AU2020311584A1 (en) 2022-01-20
WO2021005034A1 (en) 2021-01-14
TW202116781A (zh) 2021-05-01
CR20220004A (es) 2022-01-31
CN114096545A (zh) 2022-02-25
AR119376A1 (es) 2021-12-15
KR20220034104A (ko) 2022-03-17
IL288987A (en) 2022-02-01
BR112021026899A2 (pt) 2022-05-10
CL2022000019A1 (es) 2022-10-21
CA3145338A1 (en) 2021-01-14
MX2022000243A (es) 2022-02-03
JP2022539604A (ja) 2022-09-12

Similar Documents

Publication Publication Date Title
CO2021007056A2 (es) Nuevos compuestos heterocíclicos
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
CO2021002382A2 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
CL2021000361A1 (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
UY37487A (es) Amidas heterocíclicas como inhibidores de quinasa
CO2022000186A2 (es) Nuevos compuestos heterocíclicos
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CO2023014721A2 (es) Compuestos heterocíclicos
CL2023000594A1 (es) Compuestos heterocíclicos
CL2020002423A1 (es) Nuevos compuestos heterocíclicos
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
EA201591497A1 (ru) Новые производные октагидропирроло[3,4-c]пиррола и их аналоги в качестве ингибиторов аутотаксина
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
CO2022002336A2 (es) Compuestos heterocíclicos
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
CO2022002000A2 (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
ECSP11011245A (es) Novedosos herbicidas
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
CO2022002339A2 (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl
CO2020002396A2 (es) Nuevos compuestos heterocíclicos fungicidas
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.